ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the ...
Lourdes Vazquez
doaj +2 more sources
Antifungal Prophylaxis in Solid Organ Transplant Recipients [PDF]
Solid organ transplantation (SOT) is a treatment method that improves quality of life and survival of patients with end-stage organ failure. Immunosuppressive treatments given to these patients may predispose to the development of invasive fungal ...
Şebnem ŞENOL +18 more
doaj +4 more sources
Habip Gedik,1 Funda Şimşek,1 Taner Yildirmak,1 Arzu Kantürk,1 Deniz Arica,2 Demet Aydin,2 Naciye Demirel,2 Osman Yokuş21Department of Infectious Diseases and Clinical Microbiology, 2Department of Hematology, Ministry of Health Okmeydani Training and
Gedik H +7 more
doaj +1 more source
Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures
Maria Adriana Cataldo, Nicola PetrosilloSecond Infectious Diseases Division, National Institute for Infectious Diseases, “Lazzaro Spallanzani”, Rome, ItalyAbstract: Fungi are a frequent cause of nosocomial infections, with an ...
Maria Adriana Cataldo, Nicola Petrosillo
doaj +2 more sources
Posaconazole is a commonly used medication for antifungal prophylaxis in patients with high-risk acute leukemia, such as acute myeloid leukemia. Despite clinical data that show that posaconazole is superior to other antifungal prophylaxis medications ...
Mayur D. Mody MD +3 more
doaj +2 more sources
Liver Transplantation Without Systemic Antifungal Prophylaxis—An Exceptional Perspective from a Single Center Experience [PDF]
Background: Invasive fungal infections (IFIs) after liver transplantation (LT) remain a concern. No universal protocol for antifungal prophylaxis in LT exists. Antifungal prophylaxis varies across European centers. Studies suggest risk stratification for
Yeşim Sardan +13 more
core +2 more sources
Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis [PDF]
ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life.
Mariarita Sciumè +9 more
wiley +2 more sources
Cost-Effectiveness of Serum Galactomannan Surveillance during Mould-Active Antifungal Prophylaxis
Serial galactomannan (GM) monitoring can aid the diagnosis of invasive aspergillosis (IA) and optimise treatment decisions. However, widespread adoption of mould-active prophylaxis has reduced the incidence of IA and challenged its use.
Ai Leng Khoo +8 more
doaj +2 more sources
Isavuconazole as primary antifungal prophylaxis in pediatric hematological patients: a clinical and pharmacokinetic analysis [PDF]
Invasive fungal diseases (IFDs) are a major threat in pediatric patients with hematologic malignancies (HMs) and hematopoietic stem cell transplantation (HSCT) recipients. Optimal antifungal prophylaxis (AFP) remains a clinical challenge.
Francesco Baccelli +15 more
doaj +2 more sources
Antifungal prophylaxis among critically ill COVID-19 patients: a meta-analysis and systematic review [PDF]
Background COVID-19-associated pulmonary aspergillosis (CAPA) affects a significant proportion of patients admitted to the ICU and is associated with increased mortality, underscoring the need for effective prophylaxis.
Huaiya Xie +6 more
doaj +2 more sources

